Table 2.
Age-adjusted breast cancer incidence rates (per 100,000) in New Jersey, by subtype and by age at diagnosis, race/ethnicity, and tumor stage, 2008–2013.
| Breast cancer subtype | Age group | 20–39 years | 40–49 years | 50–64 years | ≥65 years | ||||
| Count | Incidence Rate (95% CI) | Count | Incidence Rate (95% CI) | Count | Incidence Rate (95% CI) | Count | Incidence Rate (95% CI) | ||
| Luminal Aa | 869 | 13.5 (12.7–14.5) | 3,884 | 92.3 (89.4–95.3) | 7,624 | 139.6 (136.4–142.7) | 8,398 | 203.3 (198.9–207.8) | |
| Luminal Bb | 270 | 4.1 (3.7–4.7) | 676 | 16.2 (15.0–17.5) | 1,179 | 21.8 (20.6–23.1) | 813 | 19.8 (18.5–21.3) | |
| Non-luminal HER2- expressingc | 121 | 1.9 (1.6–2.3) | 287 | 6.8 (6.1–7.7) | 611 | 11.3 (10.4–12.2) | 377 | 9.2 (8.2–10.1) | |
| Triple-negatived | 310 | 4.8 (4.3–5.3) | 711 | 17.1 (15.9–18.5) | 1,250 | 23.0 (21.8–24.3) | 1,075 | 26.0 (24.5–27.7) | |
| New Jersey Population | 6,712,391 | 4,104,990 | 5,408,652 | 4,226,407 | |||||
| Breast cancer subtype | Race/ethnicity | 20–39 years | 40–49 years | 50–64 years | ≥65 years | ||||
| Count | Incidence Rate (95% CI) | Count | Incidence Rate (95% CI) | Count | Incidence Rate (95% CI) | Count | Incidence Rate (95% CI) | ||
| Luminal Aa | 15,873 | 72.2 (71.0–73.3) | 1,996 | 51.7 (49.5–54.1) | 1,049 | 44.3 (41.5–47.1) | 1,724 | 45.3 (43.1–47.5) | |
| Luminal Bb | 2,070 | 10.1 (9.7–10.6) | 342 | 8.7 (7.8–9.7) | 203 | 8.0 (6.9–9.2) | 305 | 7.6 (6.8–8.6) | |
| Non-luminal HER2- expressingc | 913 | 4.4 (4.1–4.7) | 213 | 5.4 (4.7–6.2) | 108 | 4.5 (3.6–5.4) | 154 | 3.8 (3.2–4.5) | |
| Triple-negatived | 2,151 | 10.4 (9.9–10.9) | 693 | 17.8 (16.5–19.2) | 162 | 6.6 (5.6–7.7) | 333 | 8.3 (7.4–9.3) | |
| New Jersey Population | 16,228,596 | 3,745,444 | 2,438,511 | 4,714,148 | |||||
NOTE: Risk estimates and 95% confidence intervals (CI) were generated using logistic regression; adjusted for age, race/ethnicity and stage at diagnosis. Counts by age group and race/ethnicity and subtype do not add up to 32,770 (which is the total number of breast cancer cases included in Table 1) due to missing data on race/ethnicity and/or breast cancer subtype among some cases.
a
Luminal A (ER+ and/or PR+/HER2-);
b
Luminal B (ER+ and/or PR+/HER2+);
c
Non-luminal HER2-expressing (ER-/PR-/HER2+);
d
Triple negative (ER-/PR-/HER2-)